OSMT

RVL Pharmaceuticals plc [OSMT] Stock Forecast

Q: What is RVL Pharmaceuticals plc stock symbol ?

RVL Pharmaceuticals plc is a US stock, located in Bridgewater of New jersey and trading under the symbol OSMT

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

OSMT Stock Summary

Earnings have grown 184.1% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

OSMT has more than 2 years of cash runway (28 months)

Has a high level of debt. Debt-to-Equity ratio of 3.56 is considered high.

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 32.8%

Earnings are expected to fall -100% next year

In the News

OSMT Financial details

Company Rating

Neutral

Market Cap

110.18M

Income

-68.27M

Revenue

36.92M

Book val./share

0.16

Cash/share

0.19

Dividend

Dividend %

Employees

302

Optionable

Shortable

Yes

Earnings

15 Nov 2021

P/E

-0.02

Forward P/E

PEG

P/S

1108875.18

P/B

0.02

P/C

5.84

P/FCF

0.22

Quick Ratio

2.52

Current Ratio

3.1

Debt / Equity

3.56

LT Debt / Equity

0.01

EPS (TTM)

-0.7

EPS next Y

EPS next Q

EPS this Y

-52.85%

EPS next Y

EPS next 5Y

EPS last 5Y

-24.85%

Revenue last 5Y

-28.37%

Revenue Q/Q

-6.5%

EPS Q/Q

100%

SMA20

SMA50

SMA100

Inst Own

Inst Trans

ROA

-21%

ROE

-76%

ROC

0.01%

Gross Margin

58%

Oper. Margin

Profit Margin

-45%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.09-1.15

52W High

+11%

52W Low

+11%

RSI

Rel Volume

0.5

Avg Volume

594.36K

Volume

296.32K

Perf Week

Perf Month

Perf Quarter

Perf Half Y

Beta

1.95992

Volatility

0%, 0%

Prev Close

Price

1.11

Change

-2.63%

OSMT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	5.82	4.58	0.46	0.26	0.55
Net income per share	-2.42	-5.17	-1.47	-1.23	-0.58
Operating cash flow per share	0.83	0.64	0.29	-0.81	-0.42
Free cash flow per share	0.74	0.56	0.24	-0.84	-0.43
Cash per share	1.56	1.83	1.88	0.65	0.5
Book value per share	8.48	2.19	1.55	1.14	0.57
Tangible book value per share	-4.58	-2.68	0.05	-0.09	-0.21
Share holders equity per share	8.48	2.19	1.55	1.14	0.57
Interest debt per share	6.4	5.57	3.72	0.77	0.67
Market cap	350.89M	366.05M	249.89M	72.74M	100.57M
Enterprise value	548.89M	543.48M	357.45M	79.94M	113.52M
P/E ratio	-3.2	-1.35	-2.81	-0.88	-1.95
Price to sales ratio	1.33	1.53	9	4.16	2.02
POCF ratio	9.34	10.91	14.21	-1.33	-2.66
PFCF ratio	10.5	12.4	17.29	-1.29	-2.61
P/B Ratio	0.91	3.19	2.66	0.95	1.97
PTB ratio	0.91	3.19	2.66	0.95	1.97
EV to sales	2.08	2.26	12.88	4.57	2.28
Enterprise value over EBITDA	6.24	8.92	-8.77	-1.09	-3.14
EV to operating cash flow	14.61	16.19	20.32	-1.46	-3
EV to free cash flow	16.43	18.4	24.73	-1.41	-2.94
Earnings yield	-0.31	-0.74	-0.36	-1.14	-0.51
Free cash flow yield	0.1	0.08	0.06	-0.78	-0.38
Debt to equity	0.7	2.38	2.36	0.62	1.13
Debt to assets	0.34	0.59	0.6	0.33	0.45
Net debt to EBITDA	2.25	2.91	-2.64	-0.1	-0.36
Current ratio	1.51	2.27	3.1	2.95	2.89
Interest coverage	-4.74	0.22	-15.08	-20.04	-14.69
Income quality	-0.34	-0.12	-0.22	0.84	0.73
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.17	0.13	0.48	0.4	0.08
Intangibles to total assets	0.74	0.55	0.25	0.57	0.54
Capex to operating cash flow	-0.11	-0.12	-0.18	0.03	0.02
Capex to revenue	-0.02	-0.02	-0.11	-0.1	-0.02
Capex to depreciation	-0.05	-0.07	-0.15	-0.22	-2.01
Stock based compensation to revenue	0.01	0.02	0.18	0.43	0.08
Graham number	21.5	15.97	7.15	5.62	2.71
ROIC	-0.14	0.01	-0.18	-0.64	-0.42
Return on tangible assets	-0.54	-1.3	-0.32	-1.34	-0.88
Graham Net	-6.33	-3.99	-2.63	-0.33	-0.34
Working capital	58.36M	96.69M	117.37M	39.27M	37.25M
Tangible asset value	-207.4M	-140.13M	2.92M	-6.32M	-18.65M
Net current asset value	-239.41M	-175.92M	-103.94M	-8.56M	-20.44M
Invested capital	0.7	2.38	2.36	0.62	1.13
Average receivables	47.03M	50.17M	23.53M	2.64M	2.58M
Average payables	30.47M	16.68M	5.81M	3.45M	3.09M
Average inventory	20.66M	22.84M	11.57M	1.33M	811K
Days sales outstanding	78.1	66.78	41.4	44.49	22.25
Days payables outstanding	64.8	27.78	346.71	381.04	92.91
Days of inventory on hand	63.53	69.66	202.95	84.54	30.26
Receivables turnover	4.67	5.47	8.82	8.2	16.4
Payables turnover	5.63	13.14	1.05	0.96	3.93
Inventory turnover	5.75	5.24	1.8	4.32	12.06
ROE	-0.29	-2.36	-0.95	-1.08	-1.01
Capex per share	-0.09	-0.08	-0.05	-0.03	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.1	0.11	0.1	0.09	0.08
Net income per share	-0.14	-0.16	-0.18	-0.12	-0.24
Operating cash flow per share	0.02	-0.11	-0.17	-0.06	-0.12
Free cash flow per share	0.02	-0.11	-0.17	-0.07	-0.13
Cash per share	0.34	0.64	0.45	0.33	0.19
Book value per share	0.7	0.74	0.52	0.4	0.16
Tangible book value per share	-0.29	-0.16	-0.19	-0.3	-0.4
Share holders equity per share	0.7	0.74	0.52	0.4	0.16
Interest debt per share	0.53	0.57	0.6	0.66	0.62
Market cap	113.67M	194.79M	111.06M	113.23M	55.65M
Enterprise value	130.67M	191.7M	124M	138.34M	94.64M
P/E ratio	-2.35	-3.37	-1.52	-2.44	-0.58
Price to sales ratio	13.46	19.44	11.32	12.82	6.74
POCF ratio	56.95	-19.29	-6.76	-19.46	-4.61
PFCF ratio	56.95	-19.24	-6.48	-15.9	-4.25
P/B Ratio	1.94	2.84	2.17	2.83	3.41
PTB ratio	1.94	2.84	2.17	2.83	3.41
EV to sales	15.47	19.13	12.64	15.66	11.46
Enterprise value over EBITDA	-8.74	-14.13	-11.98	-29.04	-12.36
EV to operating cash flow	65.46	-18.99	-7.55	-23.78	-7.85
EV to free cash flow	65.46	-18.94	-7.24	-19.42	-7.22
Earnings yield	-0.11	-0.07	-0.16	-0.1	-0.43
Free cash flow yield	0.02	-0.05	-0.15	-0.06	-0.24
Debt to equity	0.76	0.83	1.13	1.44	3.56
Debt to assets	0.36	0.36	0.45	0.52	0.68
Net debt to EBITDA	-1.14	0.23	-1.25	-5.27	-5.09
Current ratio	2.17	3.3	2.89	2.34	0.38
Interest coverage	-63.55	3.54	-5.87	-1.4	-6.98
Income quality	-0.16	0.7	0.9	0.5	0.5
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.14	0.1	0.09	0.07	0.07
Intangibles to total assets	0.67	0.53	0.54	0.63	0.65
Capex to operating cash flow	0	0	0.04	0.22	0.09
Capex to revenue	0	0	-0.07	-0.15	-0.13
Capex to depreciation	0	-0.26	-7	-14.02	-11.13
Stock based compensation to revenue	0.14	0.08	0.09	0.06	0.03
Graham number	1.51	1.61	1.46	1.03	0.94
ROIC	-0.15	-0.11	-0.1	-0.11	-0.29
Return on tangible assets	-0.29	-0.2	-0.31	-0.28	-0.81
Graham Net	-0.43	-0.26	-0.3	-0.37	-0.48
Working capital	21.63M	49.43M	37.25M	21.94M	-42.64M
Tangible asset value	-24.55M	-14.51M	-18.65M	-29.75M	-39.52M
Net current asset value	-26.13M	-15.9M	-20.44M	-32.76M	-43.33M
Invested capital	0.76	0.83	1.13	1.44	3.56
Average receivables	9.7M	2.56M	3.16M	2.46M	1.91M
Average payables	5.08M	6.22M	4.71M	2.52M	2.58M
Average inventory	683K	574.5K	702.5K	498.5K	784.5K
Days sales outstanding	19.53	29.46	27.82	19.15	21.06
Days payables outstanding	219.73	249.61	84.62	102.96	117.01
Days of inventory on hand	21.34	22.13	27.56	8.34	62.71
Receivables turnover	4.61	3.06	3.24	4.7	4.27
Payables turnover	0.41	0.36	1.06	0.87	0.77
Inventory turnover	4.22	4.07	3.27	10.79	1.44
ROE	-0.21	-0.21	-0.36	-0.29	-1.46
Capex per share	0	0	-0.01	-0.01	-0.01

OSMT Frequently Asked Questions

What is RVL Pharmaceuticals plc stock symbol ?

RVL Pharmaceuticals plc is a US stock , located in Bridgewater of New jersey and trading under the symbol OSMT

What is RVL Pharmaceuticals plc stock quote today ?

RVL Pharmaceuticals plc stock price is $1.11 today.

Is RVL Pharmaceuticals plc stock public?

Yes, RVL Pharmaceuticals plc is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 594.36K
Market Capitalization 110.18M
Employee 302
CEO Mr. Brian Markison
Headquarters Bridgewater,NEW JERSEY,US
IPO Date 2018-10-12
Website https://www.osmotica.com

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.